|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Immunomedics, Inc. (IMMU) Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma
6/13/2012 9:31:36 AM
MIAMI BEACH, Fla., June 13, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported initial clinical experience with a combination of epratuzumab, the Company's humanized anti-CD22 antibody, labeled with the radioisotope, yttrium-90 (90Y), and veltuzumab, the Company's humanized anti-CD20 antibody, in patients with relapsed aggressive non-Hodgkin lymphoma (NHL).
|
|
|
|
|
|
|
|
|
|
|